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Circulating vascular endothelial growth factor is not increased ment of the presenting episode, the majority of children
during relapses of steroid-sensitive nephrotic syndrome. follow a relapsing/remitting course, necessitating re-
Background. An uncharacterized circulating factor that in- peated courses of corticosteroids and other immunosup-creases vascular permeability has previously been described in
pressive therapies. Although there is considerable evi-childhood steroid-sensitive nephrotic syndrome (SSNS). The
dence supporting a central role for the immune systemaim of this study was to determine whether this factor is vascu-
lar endothelial growth factor (VEGF), the recently described in the disease pathogenesis [1], the precise etiology is, as
endothelial cell mitogen and enhancer of vascular permeability. yet, undetermined, and histologic examination of renal
Methods. Plasma and urine VEGF levels were measured in biopsy tissue does not reveal evidence of a classic immu-children with SSNS in both relapse and remission and in nor-
nologically mediated inflammatory process involving ei-mal age- and sex-matched controls. Semiquantitative reverse
ther antibody and complement deposition or interstitialtranscriptase-polymerase chain reaction studies investigating
VEGF mRNA expression were performed on peripheral blood cell infiltration.
mononuclear cells isolated from children with SSNS in relapse Over the past 20 years, a number of groups have inves-
and controls. In two experimental models (one-hour and three- tigated an uncharacterized factor with permeability-day follow-up postinfusion), Sprague-Dawley rats were intra-
enhancing properties detected in the supernatant of pe-venously administered 50 mg rVEGF to determine whether
ripheral blood mononuclear cells (PBMCs) isolated fromthis induced either proteinuria or glomerular histologic change.
Results. Plasma VEGF levels and urine VEGF/creatinine patients with SSNS. PBMC supernatant from SSNS pa-
ratios were not elevated in SSNS relapse compared with remis- tients in relapse, when injected into guinea pig skin in
sion and control samples. Peripheral blood mononuclear cell
the Miles assay [2] produced an increase in local capillaryVEGF mRNA expression was no different in SSNS patients
permeability that was not observed upon injection withcompared with controls. The administration of VEGF to rats
induced an acute reversible fall in systemic blood pressure supernatant from SSNS patients in remission and normal
but did not result in the development of either proteinuria or controls [3, 4], CD41 lymphocytes being later shown to
glomerular histologic change. be the predominant source of this factor [5]. Infusion of
Conclusion. Increased circulating VEGF levels are not re-
stimulated PBMC supernatant from patients with SSNSsponsible for the proteinuria observed during relapses of SSNS.
into the rat renal artery has been shown to produceFurther studies are warranted to investigate intrarenal VEGF
expression. a reduction in colloidal iron staining of the basement
membrane, indicative of loss of anionic charge and foot
process fusion [6], and also to increase urinary protein
Childhood steroid-sensitive nephrotic syndrome excretion in the first 12-hours postinfusion [7]. T-cell
(SSNS) is characterized by the abrupt onset of protein- hybridomas from peripheral blood T cells isolated from
uria, which, if untreated, rapidly results in the develop- SSNS patients in relapse have also been shown to induce
ment of generalized edema. Following successful treat- proteinuria in the rat [8]. In a further model, Bakker et al
cultured isolated Con A-stimulated monocytes from pa-
tients with SSNS and other proteinuric glomerulopathiesKey words: vascular endothelial growth factor, proteinuria, childhood
nephrotic syndrome, VPF, edema. with slices of rat kidney [9]. Colloidal iron staining was
significantly reduced in a majority of SSNS cultures com-Received for publication July 24, 1998
pared with a minority of those of other glomerulopathies.and in revised form October 19, 1998
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characterized substance was termed vascular permeabil- 1999 by the International Society of Nephrology
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ity factor, although no purified cloned product emerged were to determine whether (a) circulating (plasma) or
urinary VEGF levels were increased in children duringfrom these studies. Furthermore, similar findings in the
Miles assay using PBMC supernatants from patients with relapses of SSNS compared with levels in children in
remission and healthy age- and sex-matched controls,other nephropathies, including IgA nephropathy [10], sug-
gest that this uncharacterized factor is not unique to SSNS (b) PBMC VEGF mRNA expression was different in
children with SSNS compared with healthy controls, andand may be circulating in any proteinuric nephropathy.
Vascular endothelial growth factor (VEGF), also (c) the administration of rVEGF resulted in the develop-
ment of proteinuria in the Sprague-Dawley rat.known as vascular permeability factor (VPF), is a disul-
fide-linked homodimer of 34 to 42 kDa. It is an endothe-
lial cell mitogen [11] that promotes angiogenesis and also
METHODS
has potent vascular permeability-enhancing properties
Vascular endothelial growth factor enzyme-linked im-[12]. Alternate splicing of mRNA results in the genera-
munosorbent assay kits were purchased from R&D Sys-tion of four protein species of 121, 165, 189, and 206
tems (Abingdon, UK). rVEGF for the animal studiesamino acids. On the basis of protein structure, particu-
was a kind gift from Dr. D. Ogilvie of Zeneca Pharma-larly the pattern of conserved cysteines and sequence
ceuticals (Alderley Edge, UK). Lymphocyte separationhomology, VEGF has been considered to be a member
medium (Optiprep) was purchased from Robins Scien-of the PDGF protein family [13].
tific (Knowle, UK). Sprague-Dawley rats were purchasedVascular endothelial growth factor mediates biological
from Charles Rivers (Margate, UK). Taq DNA polymer-function by interaction with two specific tyrosine kinase
ase, Superscripte reverse transcriptase, RNase inhibitor,receptors on endothelial cells: fms-like tyrosine kinase
oligo (dT)12–18, 100 bp DNA ladder, and dNTP solutions(f lt-1) [14] and kinase insert domain containing receptor
were all purchased from Life Technologies (Paisley, UK).(KDR) [15], also known as VEGFR1 and VEGFR2,
respectively. In an experimental model, a systemic injec-
Plasma and urine VEGF levels in childhood SSNS
tion of VEGF has been reported to induce proteinuria
Plasma and urine samples were collected from children(abstract; Iijima et al, J Am Soc Nephrol 3:514, 1992).
with relapsing SSNS during disease relapse and re-Topical application of VEGF to the rat cremaster muscle
mission and from age- and sex-matched normal controls.[16] and infusion of VEGF into the parietooccipital cor-
Children receiving regular immunomodulatory therapytex of mice [17] have been shown to increase capillary
and those who had received corticosteroids within sixpermeability within 30 minutes. Coincident with these
weeks or alkylating agents (cyclophosphamide or chlor-local changes in capillary endothelium is the dynamic,
ambucil) within six months were excluded from thetemporal appearance of interendothelial gaps and the
study. Ethical approval was granted by the Salford Areaformation of fenestrae-like openings.
Health Authority Ethical Committee. Relapse samplesVascular endothelial growth factor is known to be
were collected early during disease relapse. Parents wereconstitutively expressed by a wide range of normal adult
asked to contact the department as soon as possible aftertissues [18], including glomerular epithelial cells [19],
the development of proteinuria, allowing samples to beand PBMCs have been reported to both express VEGF
collected before the children became clinically nephroticmRNA [20] and to secrete VEGF protein (abstract; Wat-
(as part of routine clinical care, families of children withson et al, J Am Soc Nephrol 7:1725, 1996). Glomerular
SSNS are instructed to test their child’s early morningendothelial cells have been shown to express mRNA for
urine for proteinuria on a daily basis using Albustixe).both VEGF receptors, f lt-1 and KDR [19]. Dysregulated
Remission samples were collected during periods of sta-VEGF expression has previously been implicated in a
ble remission. Control samples were collected from oth-number of pathological situations, including tumor angi-
erwise healthy children undergoing minor elective surgi-ogenesis/metastasis [21], rheumatoid arthritis [22, 23],
cal procedures under general anesthesia. Samples werediabetic retinopathy [24, 25], ovarian hyperstimulation
collected within two minutes of induction of anesthesiasyndrome [26], and glomerular disease associated with
prior to the commencement of surgery. A separate veni-mesangial proliferation (abstract; Iijima et al, J Am Soc
puncture site was chosen rather than using the intrave-Nephrol 6:923, 1995).
nous cannula to obtain samples in order to avoid anyIn view of the seemingly considerable body of evi-
contamination by intravenous anesthetic agents. Blooddence to support a potential role for VEGF in the patho-
was collected into Becton and Dickenson ethylenedi-genesis of SSNS, we undertook the following series of
aminetetraacetic acid (EDTA) blood tubes (0.072 mlinvestigations. Our hypothesis was that exposure of glo-
7.5% EDTA per 3 ml sample), and centrifugation ofmerular capillary cells to circulating VEGF or VEGF
samples (2000 r.p.m. for 10 min) and separation ofproduced locally in the kidney would modulate endothe-
plasma was performed within two hours of venipuncture.lial permeability through a noninflammatory mechanism,
thus inducing albuminuria. The specific aims of the study Plasma was used in preference to serum, as we have
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previously shown that a significant increase in measured cDNA template and competitive fragment DNA for the
VEGF and b-actin RT-PCR amplifications. RT-PCR ofVEGF levels occurs upon clotting of blood due to plate-
let VEGF release [27]. Early morning urine samples were the samples was carried out in a 20 ml reaction overlaid
with paraffin oil containing 1/25th volume (4%) of thecollected into universal containers. Plasma and urine
samples were stored in multiple aliquots at 2808C prior cDNA reaction; 10 pmol of each primer (with the for-
ward primer 59 fluorescently end labeled with a CY5eto assaying.
Plasma and urine VEGF levels were measured using tag); 0.75 mm of each dNTP; 10% dimethyl sulfoxide;
3.5 mm MgCl2; 16.6 mm (NH4)2SO4; 67 mm Tris-HCl, pHa monoclonal antibody (mAb)-mediated capture ELISA
(R&D Systems). Urinary protein levels were measured 8.0; 85 mg/ml bovine serum albumin and 0.5 units of Taq
DNA polymerase; and either 10 fg of VEGF or 1 pgusing a benzethonium chloride-binding assay (Hitachi
911 autoanalyzer), and urinary creatinine levels were of b-actin competitive DNA fragment as appropriate.
Thermal cycling conditions consisted of an initial dena-measured using a kinetic Jaffe method (Hitachi 911 au-
toanalyzer). Urine VEGF levels were expressed as a turation step at 948C for three minutes followed by 30
cycles for VEGF and 25 cycles for b-actin at 948C forVEGF/creatinine ratio to correct for variation in urine
concentration between samples. one minute; 558C for one minute and 658C for one minute
for VEGF and b-actin, respectively; and 728C for one
Semiquantitative VEGF mRNA expression in PBMCs minute, with a final extension step at 728C for five min-
in childhood SSNS utes. VEGF transcript expression was quantitated for
each isoform using the ALFexpress DNA analysis sys-At the time of venous sampling for obtaining plasma
samples, a further sample of blood was collected from tem (Pharmacia Biotech, Quebec, Canada). One microli-
ter of PCR product was electrophoresed in duplicatechildren with SSNS in relapse into Becton and Dickenson
EDTA tubes for isolation of PBMCs. These were isolated through a 6% 39:1 acrylamide:bis-acrylamide 1 3 TBE
gel, and average values of peak fluorescence were deter-from the whole blood samples by the centrifugation of
cells through lymphocyte separation medium (Flow Lab- mined. Transcript values were divided by competitive
fragment values to correct for inter-PCR variation andoratories, Irvine, UK). Total RNA was extracted from
PBMC cell pellets using a modification of the guanidin- were then expressed as a ratio of the peak area fluores-
cence of the transcript of interest over the b-actin tran-ium thiocyanate-phenol-chloroform method [28]. cDNA
was synthesized from 5 mg of total RNA using Super- script.
scripte reverse transcriptase and oligo (dT)12–18 according
Experiments to determine whether the administrationto the manufacturer’s instructions. Semiquantitative re-
of rVEGF induces proteinuria in theverse transcriptase-polymerase chain reaction (RT-PCR)
Sprague-Dawley ratwas performed using previously described primers known
to amplify all reported VEGF splice variants [20]. In addi- Short-term follow-up model. All animal care was in
accordance with United Kingdom Home Office guide-tion, primers designed to amplify b-actin [29] were used
to control for variation in cDNA template concentration, lines. Ten male Sprague-Dawley rats (mean weight
244.9 g 6 sd 27.7 g; Charles Rivers, UK) were anesthe-and competitive DNA fragments were constructed for
both PCR reactions to control for inter-PCR amplifica- tized by the administration of a bolus of 100 mg/kg of
intraperitoneal thiopentone; further intraperitoneal dosestion variation.
A VEGF competitive DNA fragment of 269 bp was of 2 mg/kg were given if necessary until surgical anesthe-
sia was attained. Following shaving of the neck and abdo-generated using the primers: forward 59CGAAGTGGT
GAAGTTCATGGATGATAGAGCAAGACAAGA men, animals were placed in the prone position on a
heated operating table. The neck vessels were exposed,AAATCCCTG39 and reverse, 59TTCTGTATCAGTC
TTTCCTGGTGAG39 (sequences in bold denote prim- and following ligation of the vessel distally, the left exter-
nal jugular vein was cannulated using PP10 tubing (Ormeers used in VEGF cDNA amplification, and the under-
scored sequence corresponds to nucleotide 460–484 Gen- Scientific, Manchester, UK). A bolus of 1 ml 0.9% saline
warmed to 378C was administered over a two-minuteBank accession no. M32977). A b-actin competitive DNA
fragment of 225 bp was generated using the primers: period, followed by a continuous infusion of 200 ml/min
to ensure that a good urine output was maintained. Theforward 59GCCGTCTTCCCCTCCATCGAAGTACC
CCATCGACGACGG39 and reverse 59TAGCAACGT right internal carotid artery was then exposed and, fol-
lowing ligation of the distal vessel, was cannulated usingACATGGCTGGGG39 (sequences in bold denote prim-
ers used in b-actin cDNA amplification, and underlined PP50 tubing and connected via a Statham pressure trans-
ducer (P23 Dc) to a Grass Polygraph (model 79C) tosequence corresponds to nucleotide 242–262 GenBank
accession no. X00351). Titration experiments were con- provide systemic blood-pressure monitoring. Only ani-
mals in which the mean arterial blood pressure (BP) wasducted (data not shown) to determine the optimum num-
ber of amplification cycles and the optimum amounts of sustained above 80 mm Hg for the entire duration of the
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experiment were accepted for inclusion into the study. A Dawley rats (mean weight 238.3 g 6 sd 15.1 g; Charles
Rivers, London, UK) were placed in metabolic cagestracheotomy was performed using a diathermy loop to
ensure a clear airway. for a two-day period prior to commencement of the
experimental period to allow complete acclimatization.A midline laparotomy incision was made, and the left
ureter was catheterized using PP10 tubing to allow col- Throughout the entire period of experimentation, ani-
mals were allowed free access to water and were fedlection of urine from the left kidney. A baseline urine
sample from the left kidney was then collected over a standard chow in powdered form to prevent food being
dragged from the feed hoppers into the main body of the30 minute period into a preweighed eppendorf. At this
point, 50 mg of rVEGF165 in a total volume of 500 ml cage (thus avoiding possible contamination of collected
urine with protein-containing feed). Room temperature0.9% saline or an identical volume of 0.9% saline alone
(5 animals in each group) were infused into the animal remained constant, and standard 12-hour light and dark
cycles were used. At 0700 hours on experimental day 1,over a 10-minute period via the external jugular vein
using a Graseby syringe pump. A dose of 50 mg was the metabolic cages were washed thoroughly, and the
first 12-hour baseline urine collection commenced. Atchosen on the basis of a previous report (abstract; Iijima
et al, J Am Soc Nephrol 3:514, 1992), suggesting that this 1900 hours on the same day, using an aseptic technique,
animals were administered either 50 mg rVEGF165 in 1dose induced proteinuria. Human rVEGF165 has pre-
viously been shown to be biologically active in rat models ml 0.9% saline or 1 ml 0.9% saline by slow intravenous
injection into a tail vein using a 23G cannula.[16], and physiological responses relating to altered vas-
cular wall function have been reported to occur rapidly Following the infusion of either VEGF or saline, urine
was collected every 12 hours for a total of 72 hours (sixin both the Miles assay [2] and a rat cremaster muscle
model [16]. The biological activity of the rVEGF165 used 12-hour samples). Urine was collected into preweighed
containers. After repeat weighing to calculate the vol-had previously been confirmed in endothelial cell mito-
genesis assays (A. Canfield, University of Manchester, ume of urine passed, the urine was microfuged to remove
debris and was stored in multiple aliquots at 2808C priorUK, personal communication). Following completion of
the 10-minute period of intravenous infusion, a further to assaying. At the end of the 72 hour period of urine
collection, the animals were sacrificed, and the left kid-four 15-minute timed collections were made, after which
the left kidney was instantly removed and divided into ney was instantly removed and placed in 10% neutral-
buffered formalin. Tissues were processed for light mi-two portions. One (for light microscopy studies) was
placed in 10% neutral-buffered formalin, and the other croscopy by the Department of Pathological Sciences,
University of Manchester, UK.(for electron microscopy studies) was placed in 2.5%
glutaraldehyde in cacodylate buffer. Animals were then Urine total protein concentrations were measured as
described earlier here. Total protein excretion was ex-sacrificed by overdosing with intravenous anesthetic. A
terminal blood sample was collected into an EDTA pressed as mg per 12-hour period, calculated using the
product of the protein concentration and the volume ofblood tube for the measurement of plasma VEGF levels
using the mAb-mediated capture assay. Tissues were urine passed.
processed for light microscopy and electron microscopy
Statistical analysisby the Department of Pathological Sciences, University
of Manchester, UK. The diameter of endothelial fenes- Plasma VEGF levels and urine VEGF/creatinine ra-
tios were shown not to be normally distributed, andtrations was measured in electron micrographs (magni-
fication 339,000). Capillary loops were selected ran- the Kruskal–Wallis test was used to compare relapse,
remission, and control values. The Mann–Whitney testdomly for measurement and with a minimum of 10
glomeruli being examined in each kidney. The mean was used to compare VEGF mRNA levels. Calculations
were performed using GraphPad Prisme (GraphPad(range) number of fenestrations measured in each kidney
was 93 (73 to 114). Software Inc., USA).
Urine volumes were calculated by reweighing the pre-
weighed eppendorfs and subtracting the pre-experimen-
RESULTS
tal from the post-experimental weights. Urine samples
Plasma and urine VEGF levels in childhood SSNSwere frozen and batched for measurement of total pro-
tein concentration using a colorimetric assay (BioRad, Twenty-two children (16 boys and 6 girls) with SSNS
were studied in relapse, and 13 (11 boys, 2 girls) wereHemel Hempstead, UK) for protein concentration based
on the Lowry assay [30]. Protein excretion from the left studied in remission. The mean (sem) age of the relapse
group was 8.7 (61.08) years, and the remission group’skidney was expressed as milligrams per hour, calculated
using the product of the protein concentration and the mean age was 9.3 (61.40) years. All children in both
relapse and remission groups were not on maintenancevolume of urine passed.
Longer term follow-up model. Eight male Sprague- immunomodulatory therapy and had not received oral
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corticosteroids in the preceding six weeks or cyclophos-
phamide in the preceding six months. Control subjects
(N 5 24) had a mean age of 7.2 (60.94) years. There
was no significant difference in the ages or male:female
ratios between the three groups.
All children had their urinary protein excretion quan-
titated by measurement of an early morning protein/
creatinine ratio (normal range less than 25 mg/mmol,
nephrotic proportion proteinuria more than 250 mg/
mmol). This confirmed the presence of nephrotic propor-
tion proteinuria in the relapse group and the absence of
proteinuria in the remission and control groups.
Plasma VEGF levels were not significantly increased
in children with SSNS in relapse (N 5 22, median 50.6
pg/ml, interquartile range 31.2 to 97.3 pg/ml) compared
with remission (N 5 13, 31.2 pg/ml, 31.2 to 39.1 pg/ml)
or normal age- and sex-matched controls (N 5 24, 61.1
pg/ml, 31.2 to 104.3 pg/ml; P 5 0.295 Kruskal–Wallis
test; Fig. 1A). Urine VEGF/creatinine ratios (Fig. 1B)
were also not significantly higher in relapse (N 5 15,
34.2 ng/mmol, 18.1 to 45.6 ng/mmol) compared with re-
mission (N 5 10, 20.1 ng/mmol, 19.2 to 30.2 ng/mmol)
or control samples (N 5 17, 23.7 ng/mmol, 18.2 to 38.0
ng/mmol; P 5 0.632 Kruskal–Wallis test).
VEGF mRNA expression in PBMCs in
childhood SSNS
Nine children with SSNS in relapse and nine normal
control children were studied. Semiquantitative RT-
PCR studies of VEGF mRNA expression in unstimu-
lated PBMCs did not show any significant difference Fig. 1. (A) Plasma vascular endothelial growth factor (VEGF) levels
in levels of VEGF121, VEGF165, or total VEGF mRNA in children with steroid-sensitive nephrotic syndrome (in relapse and
remission) and age- and sex-matched normal controls. P 5 0.295,between the two groups (Table 1).
Kruskal–Wallis test. (B) Urinary VEGF/Cr ratios in children with ste-
roid-sensitive nephrotic syndrome (in relapse and remission) and age-Experiments to determine whether the administration and sex-matched normal controls. P 5 0.632, Kruskal–Wallis test. Hori-
of rVEGF induces proteinuria in the zontal bars denote median values.
Sprague-Dawley rat
Short-term follow-up model. Both VEGF and control
groups of animals were of similar weight [VEGF group
the relative volume expansion produced by the continu-mean (6sd) weight 250.2 g (616.5 g), control group
ous saline infusion (Fig. 2B). In the VEGF-administered239.6 g (67.7 g), P 5 NS, unpaired t-test]. There was
animals that received an identical volume of 0.9% salineno significant difference between the BPs of the two
during the period of experimentation, there was a fallgroups of animals in the 30-minute run-in period prior
in urine output to below baseline levels for the first 45-to the commencement of the infusion. In animals admin-
minutes after completion of the VEGF infusion. Urinaryistered VEGF, there was an acute and precipitous fall
protein excretion similarly fell in the VEGF-treatedin systemic BP immediately upon commencement of the
group, with excretion remaining constant in the salineVEGF infusion (Fig. 2A). The mean BP at two-minutes
control animals (Fig. 2C). Terminal plasma VEGF levelsafter commencement of the VEGF infusion was signifi-
in control animals were all below the background detec-cantly lower than baseline (t0) values (P 5 0.003, paired
tion limit of the mAb-mediated capture assay, whereast-test). This fall in BP was transient, with recovery to
in VEGF-treated animals, despite 1 in 10 dilution ofclose to preinfusion levels occurring by 30-minutes post-
samples, plasma levels were in gross excess of the upperinfusion. No similar effect was seen in the control animals
detection limit of the assay, indicating circulating VEGFadministered a 1 ml bolus of 0.9% saline.
levels to be in excess of 20 ng/ml. Light and electronIn the control animals, urine output increased steadily
throughout the period of experimentation secondary to microscopy studies on renal tissue submitted from three
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Table 1. Median (interquartile range) VEGF mRNA/b-actin mRNA fluorescence ratios in SSNS (relapse)
and normal age-sex matched controls
Total VEGF mRNA/ VEGF121 mRNA/ VEGF165 mRNA/
b-actin mRNA b-actin mRNA b-actin mRNA
SSNS N 5 9 0.491 (0.121–0.516) 0.383 (0.103–0.397) 0.094 (0.027–0.118)
Controls N 5 9 0.336 (0.139–1.156) 0.295 (0.1–0.871) 0.077 (0.024–0.285)
P a NS NS NS
Abbreviations are: VEGF, vascular endothelial growth factor; SSNS, steroid-sensitive nephrolic syndrome; NS, not significant.
a Mann-Whitney test
VEGF-administered and three control animals revealed In addition to failing to detect increased circulating
no abnormality in either group. In particular, electron VEGF levels in human subjects with SSNS, it was also
microscopy studies showed no evidence of podocyte foot not possible to induce proteinuria in the Sprague-Dawley
process abnormality in VEGF-treated animals, and the rat by the administration of recombinant human VEGF
diameter of endothelial cell fenestrations was not sig- using both a short-term and a longer term model. The
nificantly greater in the VEGF-treated group than the choice of dose of VEGF, mode of administration, and
saline control group [median (interquartile range) diam- time courses studied warrant further discussion. As pre-
eter 103 nm (77 to 128 nm) and 120 (85 to 154 nm), viously outlined, a dose of 50 mg was chosen because a
respectively, P 5 0.17, Mann–Whitney test]. previous report suggested that this would induce protein-
uria (abstract; Iijima et al, J Am Soc Nephrol 3:514, 1992);
Longer term recovery model if proteinuria had occurred, further experiments would
Both VEGF-treated and saline control animals were have been performed using lower, more physiological
of similar weights [VEGF group mean (6sd) weight VEGF doses. VEGF was administered systemically
235.5 g (67.9 g), control group 241.0 g (68.1 g), P 5 rather than directly into the renal artery or descending
NS, unpaired t-test]. All animals were inspected on a aorta to avoid any possible renal hypoxia associated with
twice-daily basis throughout the entire experimental pe- vessel cannulation, hypoxia being well recognized as a
riod and remained well, with no adverse clinical signs. potent stimulus for up-regulation of VEGF mRNA ex-
Urine output showed significant diurnal variation in both pression [31–33]. Widespread binding of administered
VEGF and saline control-treated animals, with increased VEGF to receptors on endothelium throughout the en-
urine production during the overnight 12-hour period tire vasculature as a potential cause of the absence of
(1900 to 0700 hr) compared with the daytime periods any observed effect was excluded by the detection of
(0700 to 1900 hr) (Fig. 3A). There was no significant high circulating levels (more than 20 ng/ml) in VEGF-
difference in urine output between the two groups. Pro- treated animals at the end of the experimental period.
tein excretion showed similar diurnal variation in both Although we did not formally test whether an even
groups (Fig. 3B). No difference in protein excretion was higher VEGF dose would result in the development of
detected between the VEGF-treated and saline control proteinuria, this would appear unlikely in view of this
animals. finding. A 60-minute preliminary follow-up period was
Light microscopy studies on renal tissue submitted chosen, as it was anticipated that any VEGF-induced
from both VEGF-administered and control animals re- changes might occur within this time frame in view of
vealed no abnormality in either group. the rapidity of biological action detected in both the
Miles assay [2] and the rat cremaster muscle model [16].
In addition to a complete absence of any evidence of aDISCUSSION
VEGF-induced functional change in the form of protein-We have clearly shown that circulating VEGF levels,
uria, there was no histologic change noted at either lightas measured using a mAb-mediated capture assay, are
or electron microscopy levels, in particular no evidencenot elevated during relapses of childhood SSNS com-
of foot process fusion or alteration in endothelial fenes-pared with both remission and normal controls. This
tration. The rationale for including the transmission elec-mAb-mediated capture assay is known to measure both
tron microscopy analysis, in particular the quantitationfree VEGF121 and VEGF165, and, therefore, it is not possi-
of the size of glomerular endothelial cell fenestrae, wasble to determine which is the predominant protein vari-
that VEGF binding to endothelium, both in vivo [16,ant being measured, although we have previously shown
17] and in vitro [34], clearly modulates the number andthat this assay detects only free VEGF and not VEGF-
structure of fenestrae as part of the mechanism control-f lt-1 complexes [27]. Semiquantitative RT-PCR studies
ling capillary permeability. If structural change in theshowed no difference in PBMC VEGF mRNA expres-
sion between SSNS relapse and control groups. endothelium had occurred in the kidney subsequent to
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VEGF administration, this may not have automatically
led to functional proteinuria through compensatory
mechanisms operating at the podocyte filtration slits.
When the duration of follow-up was increased, neces-
sitating the use of metabolic cages, again, neither pro-
teinuria nor morphological change was induced by the
systemic administration of VEGF.
Rats injected with VEGF in the short-term (60-min
follow-up) model underwent an acute fall in systemic
BP observed immediately upon commencement of the
VEGF infusion, with the mean BP two-minutes postcom-
mencement of the infusion being significantly lower than
that at commencement of the infusion. An identical ef-
fect has previously been reported following the infusion
of fibroblast growth factor, which appears to be related
to increased nitric oxide (NO) synthesis and resultant
vasodilation [35]. In vitro studies on vessels isolated from
rabbits have shown that VEGF produces a dose-depen-
dent rise in NO [36], and the in vivo infusion of VEGF
into the coronary circulation has been shown to stimulate
NO-dependent dilation of coronary microvessels [37].
Therefore, it appears likely that the observed hemody-
namic changes were secondary to NO-mediated vasodi-
lation, and it confirms that the injected rVEGF prepara-
tion had significant biological activity at the dose used.
These data refute our hypothesis that high circulating
VEGF levels mediate the development of proteinuria in
SSNS and that the circulating factor previously detected
by others [3–9] was VEGF.
These rat studies clearly demonstrate that the glomer-
ular capillary endothelium is insensitive to the effects of
VEGF circulating in blood. The fact that VEGF was
detected at levels in excess of 20 ng/ml at the end of the
experiment is important, as it rules out the possibility of
neutralization of VEGF by high circulating levels of f lt-1
acting as a natural antagonist; the assay does not detect
VEGF in the form of such complexes. The glomerular
endothelium is reported to express both VEGF recep-
tors, f lt-1 and KDR [19], and ought therefore to be
sensitive to the biological action of VEGF similar to
other endothelial beds. One potential explanation for
the disparity between the results of this study and of
those demonstrating increased permeability in other en-
dothelial beds [2, 16] is the direction of presentation of
VEGF to the endothelium. We presented VEGF via
Fig. 2. (A) Blood pressure (mean 6 SEM) in Sprague-Dawley rats prior
to, during, and for 60 minutes after the administration of rVEGF165 (50
mg; N 5 5) or 0.9% saline (N 5 5). Symbols are: (j) VEGF-administered
animals; (m) saline-administered animals. (B) Urine output (mean 6
sem) in Sprague-Dawley rats prior to and following administration of
rVEGF165 (50 mg; N 5 5) or 0.9% saline (N 5 5). (C) Urinary protein
excretion (mean 6 sem) by Sprague-Dawley rats following administration
of rVEGF165 (50 mg; N 5 5) or 0.9% saline (N 5 5).
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crete VEGF into the glomerular basement membrane,
and in this scenario, glomerular endothelial cells would
also naturally encounter VEGF from an abluminal direc-
tion. We have previously reported preliminary data sug-
gesting that podocyte VEGF mRNA expression is in-
creased in minimal change disease (abstract; Nephrol
Dial Transplant, in press), and this is currently under
further investigation. Although these studies have clearly
shown that VEGF is not the circulating factor previously
described in SSNS, a more indirect role for podocyte-
derived VEGF in the disease pathogenesis cannot be
excluded and warrants further study.
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